Document:

Exhibit 4.56

 

 

	5 May 2015	

 

Strictly Private & Confidential

 

Julian Gangolli

 

Dear Julian,

 

In addition to your offer letter, which sets
out the elements of our employment offer, I am now writing to summarize the discretionary/non-contractual benefits that you would
be eligible to receive during your employment at GW Pharmaceuticals Inc (the “Company”).

 

A summary of the discretionary/non-contractual
benefits for this role is outlined below:

 

		·	As the Company does not currently have
a healthcare benefits program established, and in the event that you do not wish to continue with coverage paid by your former
employer, we will reimburse you reasonable costs of your medical premiums so you can establish your own health insurance coverage.
Once the Company’s medical benefits program is established, this contribution will cease and you will be eligible to enroll
in the company benefits program.

 

		·	It is also our intent to establish a Death-In-Service
life insurance. This benefit would be fully paid for by the Company on your behalf. 

 

		·	It is our intent to establish a 401K Plan
for our employees as soon as possible. Once established, you will be eligible to enroll in the program and receive the Company’s
matching contribution. 

 

As soon as these, and other benefit programs,
are established, enrollment and participation details will be communicated to all employees of the Company.

 

You will be entitled to seek reimbursement
of all business expenses that you incur, including the costs of maintaining a business telephone line, mobile phone, etc., in accordance
with our US Travel and Expense Policy.

 

In addition to the above benefits you will
be entitled to participate in the discretionary GW Pharmaceuticals group long term incentive and bonus scheme as follows:

 

     

     

    

  

		·	You will, in addition to your salary, be eligible for a discretionary bonus. In accordance with
the remuneration policy approved by the Company’s shareholders, the terms and amount of this bonus will be decided from time
to time by the Remuneration Committee in its sole discretion.

 

		·	As soon as possible after the date of commencement
of employment (subject to any close period restrictions), and subject to ratification from the Remuneration Committee, the Company
will grant you equity-based incentives equivalent to 4.5 X salary ($1.8m) through 3 instruments:

 

-              25% as Restricted Stock
Awards

 

These awards vest evenly over a
4 year period, based solely on employment. They represent shares exercised at nominal par value (0.1p), hence the recipient retains
full value of shares at the market price at the time of vesting.

 

-              50% as Performance Stock
Units

 

These awards vest after 3 years
and are dependent on specific company performance criteria. They represent shares exercised at nominal par value (0.1p), hence
the recipient retains the full value of the shares at the market price at the time of vesting.

 

It is expected that 50% of these
PSUs will vest upon submission of an NDA to the FDA for Epidiolex, and that the remaining 50% will vest upon achievement of FDA
approval for Epidiolex. Although these proposed performance conditions have been discussed with the Remuneration Committee, the
Committee has the discretion to revise these performance conditions at the time of the awards being granted to you.

 

-              25% as Market Price Options

 

These awards vest after 3 years’
service. Exercise price equals the market price at grant, hence value linked to share price growth between grant of option and
vesting period

 

The number of shares will be based on Black
scholes valuations (or similar appropriate valuation method) of each option type on the date of grant.

 

At the end of each calendar year, subject to
satisfactory personal and company performance, you may be eligible to receive additional grants of equity-based incentives

 

All of the above benefits remain entirely at
the discretion of the Company and may change from time to time.

 

We are all delighted that you are joining us
and look forward to working with you.

 

     

     

    

  

Sincerely,

 

/s/ Justin Gover

 

Justin Gover

Chief Executive OfficerExhibit 4.57

 

EFFECTIVE DATE 21 JULY 2015

 

(1) GW PHARMACEUTICALS PLC

 

(2) JULIAN GANGOLLI

 

SERVICE AGREEMENT

 

     

     

    

 

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	1.	INTERPRETATION	1
	 	 	 
	2.	APPOINTMENT	4
	 	 	 
	3.	DUTIES DURING THE APPOINTMENT	4
	 	 	 
	4.	CONFIDENTIALITY	7
	 	 	 
	5.	LOCATION	8
	 	 	 
	6.	SALARY	9
	 	 	 
	7.	INTENTIONALLY OMMITTED	9
	 	 	 
	8.	EXPENSES	9
	 	 	 
	9.	INTENTIONALLY OMMITTED	9
	 	 	 
	10.	INTENTIONALLY OMMITTED	9
	 	 	 
	11.	INTENTIONALLY OMMITTED	10
	 	 	 
	12.	INTELLECTUAL PROPERTY RIGHTS	10
	 	 	 
	13.	TERMINATION	12
	 	 	 
	14.	OBLIGATIONS RELATING TO TERMINATION	14
	 	 	 
	15.	STATEMENTS AND FURTHER ASSISTANCE	15
	 	 	 
	16.	DATA PROTECTION	15
	 	 	 
	17.	USE AND MONITORING OF EQUIPMENT	17
	 	 	 
	18.	RESTRICTIVE COVENANTS	17
	 	 	 
	19.	CONTINUING OBLIGATIONS	20
	 	 	 
	20.	CORPORATE RECONSTRUCTION	21
	 	 	 
	21.	AGREEMENTS WITH OTHER COMPANIES IN THE GROUP	21
	 	 	 
	22.	ADDITIONAL TERMS	21
	 	 	 
	23.	NOTICES	21
	 	 	 
	24.	MISCELLANEOUS	22

 

     

     

    

 

SERVICE AGREEMENT

 

		MADE WITH EFFECT FROM:	21 July 2015

 

PARTIES:

 

		(1)	GW PHARMACEUTICALS PLC whose registered office is at Sovereign House, Vision Park, Chivers
Way, Histon, Cambridge CB24 9BZ, UK (the “Company”); and

 

		(2)	JULIAN GANGOLLI  (“the Executive”).

 

IT IS AGREED as follows:

 

		1.	INTERPRETATION

 

		1.1	Definitions:

 

In this Agreement the following words
and phrases have the meanings given below:-

 

		“Adverse Event”	includes,
but is not limited to, any development in the economy generally or in the financial sector which is or may be a Detriment;

 

		“Appointment”	the employment
of the Executive on the terms of this Agreement;

 

		“Board”	the board of
directors of the Company, as constituted from time to time, including any duly appointed committee or nominee of the Board;

 

		“Bribe”	a financial
or other advantage offered to a person, which is intended to induce that person to perform improperly a function or activity,
or as a reward for the improper performance of a function or activity or the offer of a promise of a financial or other advantage
where the acceptance of the advantage itself constitutes the improper performance of a function or activity;

 

    	 	1	 

     

    

 

		“Business Unit”	means
the business division or unit in relation to which any bonus decision was taken and may, where appropriate, include more than
one business division or unit as the case may require;

 

		“Data Controller”	shall
have the meaning given to it by Section 1(1) Data Protection Act 1998;

 

		“Detriment”	a
detriment which the Company, in good faith, considers has or may have an adverse impact on the Company, or any relevant associated
Company or any relevant Business Unit, including, but not limited to, any of the following:

 

		-	any financial loss (whether impacting the financial results for the current year or a previous
year);

 

		-	any reputational damage;

 

		-	a restatement in any of the Group accounts;

 

		-	any sanction from any government agency or any regulatory authority;

 

		“Effective Date”	A
date to be agreed in writing between the parties within 30 days of the date of this Agreement, such date to be no late than 1
January 2013;

 

		“Executive’s Personal Data”	Personal
Data and Sensitive Personal Data;

 

		“Group”	any
of the following from time to time: the Company, its subsidiaries and subsidiary undertakings and any holding company or parent
undertaking of the Company and all other subsidiaries and subsidiary undertakings of any holding company or parent undertaking
of the Company, where “holding company”, “parent undertaking”, “subsidiary” and “subsidiary
undertaking” have the meanings given to them in the Companies Act 2006;

 

    	 	2	 

     

    

 

		“London Stock Exchange”	London
Stock Exchange plc;

 

		“Personal Data”	personal
data (as defined by s.1(1) Data Protection Act 1998) about the Executive;

 

		“Remuneration Committee”	the
committee of directors of the Company as appointed by the Board to determine the remuneration from time to time of the Company’s
executives;

 

		“salary”	the
salary payable from time to time under Clause 6.1;

 

		“Sensitive Personal Data”	data
about the Executive’s:

 

		(i)	racial or ethnic origins;

 

		(ii)	political opinions;

 

		(iii)	religious beliefs or other beliefs of a similar nature;

 

		(iv)	membership of a trade union;

 

		(v)	physical or mental health or condition;

 

		(vi)	sexual life; or

 

		(vii)	commission or alleged commission of any offence, or any proceedings for any offence committed or
alleged to have been committed by him, the disposal of such proceedings or any sentence of any court in connection with such proceedings;

 

		“termination”	the
ending of the Appointment however it arises and irrespective of its cause or manner but excluding wrongful termination by the
Company in relation to Clause 18;

 

		“TUPE”	the
Transfer of Undertakings (Protection of Employment) Regulations 2006; and

 

    	 	3	 

     

    

 

		“UKLA”	the
Financial Services Authority in its capacity as the competent authority for the purposes of the Financial Services and Markets
Act 2000.

 

		1.2	Construction:

 

		(a)	References to acting directly or indirectly include acting alone or jointly with or on behalf of
or by means of another person and/or giving advice or providing services with a view to assisting another person.

 

		(b)	References to a person include an individual, firm, corporation and any other organisation however
it is constituted and words denoting the singular include the plural and vice versa.

 

		(c)	References to an individual holding a position in the Company or the Group mean the holder of that
position from time to time or his nominee or such other representative as the Board may nominate.

 

		(d)	References to statutory provisions are construed as references to those provisions as amended or
re-enacted from time to time (whether before or after the date of this Agreement) and references to documents are construed as
references to documents as replaced or amended from time to time after the date of this Agreement.

 

		2.	APPOINTMENT

 

		2.1	Upon and subject to the terms of the Appointment, the Company will from the Effective Date employ
the Executive as President, North America and the Executive agrees to serve the Company in that capacity, or in such other capacity
of similar status as may reasonably be required of him from time to time by the Board.

 

		2.2	The Executive acknowledges that he is not entering into this Agreement in reliance upon any representation,
warranty or undertaking which is not contained in this Agreement.

 

		3.	DUTIES DURING THE APPOINTMENT

 

		3.1	The Executive will (unless prevented by ill health or injury) devote no fewer than 12 days of his
working time per annum during the Appointment to the business of the Company and will not without the prior written consent of
the Board (such consent not to be unreasonably withheld):

 

    	 	4	 

     

    

 

		(a)	accept any other appointment, work for or be directly or indirectly engaged in or concerned with
the conduct of any other business (other than the business of GW Pharmaceuticals Inc.); or

 

		(b)	be directly or indirectly financially interested in any business which may be considered competitive
to the business of the Company (and which therefore compromises his ability to perform his duties to the Company under this contract),
other than through his holding or being interested in bona fide investments representing not more than three per cent of any class
of shares or securities in any company listed or dealt in on any recognised stock exchange.

 

		3.2	During the Appointment the Executive will:-

 

		(a)	loyally and diligently perform such duties and exercise such powers for the Group as the Board
may from time to time reasonably require, and accept without further payment other offices within the Group;

 

		(b)	keep the Board properly and regularly informed about the business of the Group and his activities
in those businesses;

 

		(c)	comply with the reasonable and lawful directions given from time to time by the Board;

 

		(d)	comply with his common law, fiduciary and statutory obligations as a director (as set out in the
Companies Act 2006), the Company’s articles of association, the City Code on Takeovers and Mergers, applicable rules and regulations
of the UKLA, London Stock Exchange and any other applicable stock exchange, the code mentioned in Clause 3.9, any other internal
codes of conduct for employees of the Group and all relevant policies and procedures;

 

		(e)	co-operate with the Group in complying with its obligations on health and safety;

 

		(f)	promptly give the Company such information as the Group may require to enable it to comply with
its legal obligations or the requirements of the UKLA, London Stock Exchange or any other applicable stock exchange; and

 

		(g)	promote and protect the interests of the Group, always giving it the full benefit of his knowledge,
expertise and skill and will not knowingly or deliberately do anything which is to its detriment.

 

    	 	5	 

     

    

 

		3.3	The Company may assign to the Executive duties which are either additional to or instead of those
referred to in Clause 3.2(a), it being understood that he will not be assigned duties which he cannot in the reasonable opinion
of the Board be expected to perform. The Company may also from time to time appoint any other person to act jointly with the Executive
in the performance of his duties and the exercise of his powers.

 

		3.4	The duties of the Executive as a director of the Company and any other member of the Group are
subject to the relevant Articles of Association from time to time.

 

		3.5	The Executive will not, without the prior written consent of the Board, directly or indirectly
receive or retain any payment or benefit, either in respect of any business transacted (whether or not by him) by or on behalf
of the Group or with a view to any such business being transacted.

 

		3.6	The Executive will not directly or indirectly:

 

		(a)	offer, promise or give a Bribe;

 

		(b)	request, agree to receive, receive or accept a Bribe; or

 

		(c)	Bribe a foreign public official;

 

either in respect
of any business transacted (whether or not by him) by or on behalf of the Group or with a view to any such business being transacted.

 

		3.7	If the Executive becomes aware of another individual who performs services for or on behalf of
the Group engaging in one of the activities set out in Clause 3.6, he must report it immediately in accordance with the Company’s
Whistleblowing Policy. Failure to act in accordance with this clause could result in the Executive being found guilty of an offence
under the Bribery Act 2010 and/or the Executive having a sanction imposed upon him pursuant to the Company’s Disciplinary Policy,
up to and including, dismissal. The Executive is expected to be familiar with the terms of any anti-bribery and corruption policies
issued by the Company or the Group from time to time.

 

		3.8	As part of and in the normal course of his duties, the Executive will:

 

		(a)	continue to carry out research into and development of the processes, products, programs, designs,
equipment, techniques and projects which are from time to time used, made or undertaken by the Group or which could be used, made
or undertaken by it, and will invent discover, design, develop or improve them for the benefit of and for use by the Group; and

 

    	 	6	 

     

    

 

		(b)	seek and pursue the adoption and development of new processes, products, programs, designs, equipment,
techniques and projects which could be used, made or undertaken by the Group.

 

		3.9	During the Appointment or while he is a director of any company in the Group the Executive will
comply and will procure, so far as he is able, that his spouse and dependant children (if any) or any trust in which he, his spouse
or dependant children may be concerned or interested in as trustee or beneficiary, comply with any code of conduct relating to
securities transactions by directors and specified employees applicable within the Group. The Executive confirms that a copy of
the current code has been given to him.

 

		4.	CONFIDENTIALITY

 

		4.1	The Executive acknowledges that during his employment with the Company he will have access to and
will be entrusted with confidential information and trade secrets relating to the business of the Group. This includes but is not
limited to information and secrets relating to:

 

		(a)	corporate and marketing strategy, business development and plans, maturing business opportunities,
sales reports and research results;

 

		(b)	business methods and processes, technical information and know-how relating to the Group’s business
and which is not in the public domain, including inventions, designs, programs, techniques, database systems, formulae and ideas;

 

		(c)	business contacts, lists of customers and suppliers and details of contracts with them and their
current or future requirements;

 

		(d)	information on employees, including their particular skills and areas of expertise, and their terms
of employment;

 

		(e)	stock levels, sales, expenditure levels and pricing policies;

 

		(f)	budgets, management accounts, trading statements and other financial reports;

 

    	 	7	 

     

    

 

		(g)	unpublished price sensitive information or potentially price sensitive information and inside information
or potential inside information relating to shares or securities listed or dealt in on any recognised stock exchange; and

 

		(h)	any document marked “confidential” or orally communicated as being “confidential”
or any information not in the public domain,

 

together,
the “Confidential Information”.

 

		4.2	The Executive will not during the Appointment (otherwise than in the proper performance of his
duties and then only to those who need to know such Confidential Information) or thereafter (except with the prior written consent
of the Board or as required by law):-

 

		(a)	divulge or communicate to any person (including any representative of the press or broadcasting
or other media);

 

		(b)	cause or facilitate any unauthorised disclosure through any failure by him to exercise all due
care and diligence of; or

 

		(c)	make use of (other than for the benefit of the Group) of

 

any Confidential Information which
may have come to his knowledge during his employment with the Company or in respect of which the Group may be bound by an obligation
of confidence to any third party. The Executive will also use his best endeavours to use adequate security measures and prevent
the publication or disclosure of any such Confidential Information. These restrictions will not apply after the Appointment has
terminated to Confidential Information which has become available to the public generally, otherwise than through unauthorised
disclosure.

 

		4.3	All notes, memoranda, and other records (however stored) made by the Executive during his employment
with the Company and which relate to the business of the Group will belong to the relevant member of the Group and will promptly
be handed over to the Company (or as the Company directs) from time to time on request and at the end of the Appointment, without
copies being kept by the Executive or anyone else on his behalf. The Executive agrees, on return of such records, to give an undertaking
that he has not retained any Confidential Information or any copies of it.

 

		5.	LOCATION

 

The Executive will perform all his
activities for the Company at locations outside of the United States of America. The Executive is expected to attend all Board
meetings in person, at the Company’s offices at 1 Cavendish Place London (or such other location as specified by the Board
from time to time).

 

    	 	8	 

     

    

 

		6.	SALARY

 

		6.1	The Company will pay to the Executive a salary at the rate of $1,550 per day spent on performing
his duties under this Agreement, including any director’s fees to which he may be entitled as a director of the Group. It is anticipated
that the Executive will spend twenty (20) days per calendar year performing his duties under this Agreement, therefore the Company
will pay the Executive the sum of $31,000 per calendar year by equal instalments in arrears at the end of each month, subject to
such deductions and withholdings as may be required by law or under the terms of this Agreement. Should the Executive notify the
Remuneration Committee that he has spent a materially different amount of time to that set out above in performing his duties under
this Agreement in a calendar year, the Remuneration Committee will review the salary paid under this Agreement for the calendar
year in question.

 

		6.2	The Remuneration Committee will review the Executive’s salary annually, but such review does not
necessarily imply an increase. The review will take account of such factors as the Remuneration Committee considers, in its absolute
discretion, to be appropriate, which may include anticipated future performance or service and/or past performance of the Executive
and/or the Company and/or the Group, although it has no obligation to take any of these factors into account. Any increase in the
rate of the Executive’s salary will normally be effective from 1 January in each year following the review.

 

		6.3	The Group may deduct from any money owed to the Executive any money which the Executive, owes or
may be owing to the Company or any other member of the Group and may set off such sums against his salary from GW Pharmaceuticals
Inc.

 

		7.	INTENTIONALLY OMMITTED

 

		8.	EXPENSES

 

The Executive will be entitled, upon
production of satisfactory evidence of payment or expenditure, to be reimbursed all reasonable out-of-pocket expenses properly
and wholly incurred by him in the performance of his duties.

 

		9.	INTENTIONALLY OMMITTED

 

		10.	INTENTIONALLY OMMITTED

 

    	 	9	 

     

    

 

		11.	INTENTIONALLY OMMITTED

 

		12.	INTELLECTUAL PROPERTY RIGHTS

 

		12.1	For the purpose of this Clause 12:

 

		(a)	“Intellectual Property” means all present and future intellectual property, including
patents, inventions, utility models, trade and service marks, trade names, domain names, rights in designs, copyrights, moral rights,
topography rights, rights in databases, trade secrets and know-how, in all cases whether or not registered or registrable and including
registrations and applications for registration of any of these and rights to apply for the same and all rights and forms of protection
of a similar nature or having equivalent or similar effect to any of these anywhere in the world (whether now known or in the future
created), in each case for the full term thereof including all renewals and extensions;

 

		(b)	“Executive Intellectual Property” means all Intellectual Property which the Executive
alone or with one or more others may make, originate, suggest, devise or develop during the period of his employment (whether or
not made, originated or developed during normal working hours) and which affect or relate to or connect to the business of the
Group from time to time or are capable of being used or adapted for use in it, other than any Executive Inventions; and

 

		(c)	“Executive Invention” means all inventions (which term bears the same meaning
as in the Patents Act 1977) which the Executive alone or with one or more others may make, originate, suggest, devise or develop
either in the course of (i) his normal duties where an invention might reasonably be expected to result from the carrying out of
his duties or (ii) duties falling outside his normal duties, but specifically assigned to him where an invention might reasonably
be expected to result from the carrying out of his duties or (iii) duties where, at the time of making the invention, because of
the nature of his duties and the particular responsibilities arising from the nature of his duties he had a special obligation
to further the interests of the Company and/or the Group.

 

    	 	10	 

     

    

 

		12.2	Any Executive Intellectual Property and any Executive Inventions will be notified and disclosed
by the Executive to the Company in an appropriate manner (bearing in mind the need to keep inventions confidential) as soon as
it comes into existence, and the Executive will keep any such Executive Intellectual Property or Executive Inventions confidential.
In the case of Executive Inventions the notification and disclosure obligations in this Clause 12.2 apply irrespective of whether
the Company is entitled to ownership of such Executive Invention by virtue of s39 Patents Act 1977. If the Company is not entitled
to ownership, it shall keep the information confidential in accordance with Clause 4 of this Agreement (unless otherwise agreed).

 

		12.3	Save as provided by law and in particular as provided by the Patents Act 1977, all Executive Inventions
or Executive Intellectual Property will belong to the Company. Insofar as permissible by law, the Executive hereby assigns to the
Company absolutely with full title guarantee and free from all encumbrances (by way of present assignment of all future rights)
all rights, title and interest in and to the Executive Invention and Executive Intellectual Property. Any Executive Invention or
Executive Intellectual Property which cannot be assigned to the Company in accordance with this Clause 12.3 will insofar as permissible
by law be held on trust by the Executive for the benefit of the Company (or relevant member of the Group) until the same are vested
absolutely in the Company.

 

		12.4	The Executive acknowledges, including for the purpose of s39 Patents Act 1977, that because of
the nature of his duties and the particular responsibilities arising from those duties, his employment with the Company carries
with it a special obligation to further the interests of the Company and other members of the Group.

 

		12.5	The Executive undertakes that, at the Company’s expense and upon request (whether during or after
the termination of the Appointment), he will execute such documents, make such applications, give such assistance and do such acts
and things as may be necessary to enable the Company or relevant member of the Group to enjoy the full benefit of this Clause 12.5,
whether during or after termination of the Appointment. This will include the giving of assistance or advice (including giving
evidence if so required) in connection with:

 

		(a)	the prosecution of any applications for the registration
of;

 

		(b)	any claims or proceedings brought to prevent or bring to an end the infringement of;

 

		(c)	all steps necessary to assign; and/or;

 

		(d)	any claims or proceedings concerning or affecting the validity of,

 

any Executive Intellectual Property
and/or any rights in any Executive Invention.

 

    	 	11	 

     

    

 

		12.6	Should the Executive fail to comply with a request under Clause 12.5, the Executive hereby grants
to any duly authorised representative of the Company an irrevocable power of attorney to sign any documents and take such other
steps as are necessary to give effect to this Clause 12.

 

		12.7	Immediately upon the termination of the Appointment or earlier at the Company’s request, the Executive
will deliver up to the Company the subject matter of, and all data relating to, all Executive Intellectual Property and Executive
Inventions (including all related documents and materials and, in the case of software, all source code in a format or formats
reasonably requested by the Company) in the Executive’s possession, custody or power; and ensure that all know-how relating to
all Executive Intellectual Property and Executive Inventions is recorded on the Company’s know-how systems or otherwise communicated
or made available to the Company.

 

		12.8	Following termination of the Appointment, the Executive:

 

		(a)	will make himself available to explain know-how or other aspects of any Executive Intellectual
Property and/or Executive Inventions, if reasonably requested by the Company; and

 

		(b)	will keep all Executive Intellectual Property and Executive Inventions confidential unless or until
they are disclosed in the public domain or otherwise cease to be confidential through no fault or act of the Executive.

 

		12.9	The Executive irrevocably waives all moral rights which he might otherwise have or be deemed to
have under Chapter IV Copyright, Designs and Patents Act 1988 or under any other similar law anywhere in the world.

 

		12.10	Save as provided by law and set out herein, the Executive has no rights to additional remuneration
or compensation in respect of any Executive Intellectual Property or Executive Invention.

 

		13.	TERMINATION

 

		13.1	The Appointment will continue until either party gives to the other not less than six months’ written
notice. Subject to future approval from the Remuneration Committee, we would expect to increase this notice period to twelve months
after you served for two years as an Executive Director.

 

    	 	12	 

     

    

 

		13.2	The Company may, notwithstanding any other provision of this Agreement and irrespective of whether
the grounds for termination arose before or after the Appointment began, at any time by notice in writing to the Executive terminate
the Appointment with immediate effect :-

 

		(a)	if a petition is presented or any order is made or any notice is issued convening a meeting for
the purpose of passing a resolution for his bankruptcy or he becomes bankrupt or makes any composition or enters into any deed
of arrangement with his creditors generally;

 

		(b)	if he is prohibited by law or by any decision of a regulatory body from being a director or taking
part in the management of the Group or ceases to be a director of the Company without the consent of the Board;

 

		(c)	if he is convicted of

 

		(i)	a criminal offence other than one which in the opinion of the Board does not affect his position
as an employee of the Company, bearing in mind the nature of his duties and the capacity in which he is employed; or

 

		(ii)	an offence relating to insider dealing;

 

		(d)	if he commits, in the opinion of the Financial Services Authority, the civil offence of market
abuse under the Financial Services and Markets Act 2000;

 

		(e)	if he is guilty of any serious default or misconduct in connection with or affecting the business
of the Group;

 

		(f)	if he commits any serious or repeated breach of his obligations of the Appointment or is guilty
of serious neglect or negligence in the performance of his duties; or

 

		(g)	if he behaves in a manner (whether on or off duty) which is likely to bring the Group into disrepute
or prejudice its interests or which seriously impairs his ability to perform his duties.

 

		13.3	If the Company wishes to terminate the employment of the Executive or if the Executive wishes to
leave the employment of the Company in either case before the expiry of the period of notice specified in Clause 13.1 and
whether or not notice has been given under that Clause, the Company may require the Executive:

 

		(a)	to perform duties not within his normal duties or to undertake special projects; or

 

    	 	13	 

     

    

 

		(b)	not to attend for work for all or any part of the period of notice (if notice has been given) or
(if notice has not been given) for a period equivalent to the notice required to be under Clause 13.1. For so long as the
Executive is not required to work during such period, he will remain an employee of the Company. He will continue to receive his
salary and other contractual entitlements except for any bonus under Clause 7 and will continue to be bound by all the terms of
this Agreement. He will not directly or indirectly work for any person, have any contact with any customer of the Group or, for
business purposes, have contact with any employee of the Group without the prior written agreement of the Board. If the Executive
is not required to attend for work under this Clause the Company shall be entitled to offset any outstanding accrued holiday due
to the Executive for each day of non-attendance.

 

		14.	OBLIGATIONS RELATING TO TERMINATION

 

		14.1	Upon the termination of the Appointment or, upon the exercise by the Company of its right under
Clause 13.3(b), the Executive will hand over to the Company all property belonging to any member of the Group relating to
its business (including but not limited to any Confidential Information and any Executive Intellectual Property and Executive Inventions)
which may be in his possession or under his control, and without him or anyone on his behalf keeping copies of any reproduceable
items or extracts from them and without having downloaded any information stored on any computer storage medium. He will, on being
requested to do so, send to the Company Secretary a signed statement that he has complied with this sub-clause;

 

		14.2	Upon the termination of the Appointment or (if earlier) upon either party giving notice under Clause 13.1
and the Company exercising its rights under Clause 13.3, the Executive will resign at the request of the Company, without
claim for compensation, from all offices held by him in the Group and from all trusteeships held by him of any pension scheme or
other trusts established by the Company or any other member of the Group. Should he fail to do so the Board is irrevocably authorised
to appoint a person in his name and on his behalf to sign any documents and take such other steps as are necessary to give effect
to such resignations. Such resignations will be given and accepted without prejudice to any claims which the Company and the Executive
may have arising out of or in connection with the Appointment and its termination.

 

		14.3	Upon the Termination of the Appointment, the Executive will have no rights as a result of this
Agreement or any alleged breach of this Agreement to any compensation under or in respect of any share options or long term incentive
plans in which he may participate or have received grants or allocations at or before the date the Appointment terminates. Any
rights which he may have under such schemes will be exclusively governed by the rules of such schemes.

 

    	 	14	 

     

    

 

		15.	STATEMENTS AND FURTHER ASSISTANCE

 

After the termination of the Appointment
the Executive :-

 

		(a)	will not at any time make any adverse, untrue or misleading statement about any member of the Group
or its officers or employees or represent himself as being employed by or connected with any such company; and

 

		(b)	will co-operate with any member of the Group for whom he performed duties by providing such reasonable
assistance as may be required in connection with any matter, where it considers that the Executive has knowledge or information
which is relevant to such claim. The provision of such assistance may include attending meetings, giving and signing statements
and attending hearings at such times and at such locations that may be convenient to the Executive. The Company will reasonably
compensate the Executive for his time on a per diem basis (with reference to his day’s salary under this contract of employment
or such other amount as the Executive can reasonably justify with reference to his usual employment terms at that time). The Company
will reimburse the Executive for his reasonable out of pocket expenses incurred in providing such assistance.

 

		16.	DATA PROTECTION

 

		16.1	For the purpose of the Data Protection Act 1998, the Company is the Data Controller in respect
of all Executive’s Personal Data processed under this Clause 16. The Executive’s Personal Data may be processed (which includes,
without limitation, the collection, retention, use and disclosure (both electronically and manually)) solely for purposes relating
to the Executive’s employment and the operation, management, security and administration of the business of the Company or any
other member of the Group. This may include but is not limited to processing done in connection with:

 

		(a)	administering and maintaining personnel records;

 

		(b)	planning, paying and reviewing salary and other remuneration
and benefits;

 

		(c)	planning, providing and administering benefits whether statutory or contractual;

 

    	 	15	 

     

    

 

		(d)	assessments of the Executive’s performance or conduct including performance appraisals and reviews
and for disciplinary and grievance procedure purposes;

 

		(e)	maintaining sickness and other absence records;

 

		(f)	maintaining health and safety records and ensuring a safe working environment;

 

		(g)	taking decisions on the Executive’s fitness to work and complying with obligations under the Disability
Discrimination Act 1995;

 

		(h)	providing references and information to future employers (whether inside the Group or outside the
Group);

 

		(i)	providing information to the appropriate external authorities for tax, social security and other
purposes as required by law to comply with any statutory duty;

 

		(j)	equal opportunities, ethnic monitoring and compliance with legal obligations in connection with
them;

 

		(k)	providing information to any future purchasers of the Company or to any transferees of the business
in which the Executive works, including but not limited to, for due diligence purposes; and

 

		(l)	planning or reviewing options, in relation to the operation or management of the Company.

 

		16.2	The Executive, by signing this agreement, acknowledges that he has been notified of the purposes
for which the Executive’s Personal Data may be processed and also consents to such processing for those purposes. Furthermore,
the Executive, by signing this Agreement, explicitly consents to the processing of Sensitive Personal Data for those purposes.

 

		16.3	The Executive’s Personal Data may be transferred to any member of the Group (or a company appointed
by them for such purposes) located in a country or territory outside the European Economic Area for any of the above purposes.
The Executive, by signing this Agreement, acknowledges that he has been notified of the purposes for which the Executive’s Personal
Data may be transferred and the recipients of such Personal Data and that he also consents to transfers for those purposes. Furthermore,
the Executive explicitly consents to the transfer of Sensitive Personal Data for those purposes.

 

    	 	16	 

     

    

 

		17.	USE AND MONITORING OF EQUIPMENT

 

		17.1	Unless he has the prior written consent of the Chairman, the Executive will not use any computer
hardware or software or any other technical equipment or systems owned, licensed or rented:

 

		(a)	by the Company for any purpose other than to carry out his proper duties; or

 

		(b)	by him or any person other than the Company for any purpose connected with the carrying out of
his proper duties.

 

		17.2	The Executive agrees that the Group may monitor, intercept or record his use of office equipment,
including but not limited to: email, the internet, his telephone and any mobile phone issued to the Executive by the Company.

 

		18.	RESTRICTIVE COVENANTS

 

		18.1	Without prejudice to Clause 3, during the Appointment and for the periods set out below after the
termination of the Appointment less in the case of Clause 18.1(a) any period during which the Executive is not required to attend
for work pursuant to Clause 13.3, he will not (except with prior written consent of the Board) directly or indirectly do or attempt
to do any of the following:

 

		(a)	for 12 months, to any material extent, undertake, carry on or be employed, engaged or interested
in any capacity in the supply or proposed supply of Competitive Services within the Territory. Competitive Services will be provided
within the Territory of any business in which the Executive is to be involved is located, or will be located, or is conducted or
will be conducted, wholly or partly within the Territory;

 

		(b)	for 12 months entice, induce or encourage a Customer to transfer or remove custom from the Company
or any other member of the Group;

 

		(c)	for 12 months solicit or accept business from a Customer for the supply of Competitive Services;
or

 

		(d)	for 12 months entice, induce or encourage an Employee to leave or seek to leave his or her position
with the Company or any other member of the Group for the purpose of being involved in or concerned with the supply of Competitive
Services, regardless of whether or not that Employee acts in breach of his or her contract of employment with the Company or any
other member of the Group by so doing.

 

    	 	17	 

     

    

 

Nothing in Clause 18.1(a)
will prevent the Executive, after the termination of his employment, from holding bona fide investments representing not more than
three per cent of any class of shares or securities in any company listed or dealt in on any recognised investment exchange; .

 

		18.2	For the purpose of this Clause 18:

 

		(a)	“Customer” means a person:

 

		(i)	who is at the expiry of the Relevant Period or who was at any time during the Relevant Period a
customer of the Company or any Associated Company (whether or not goods or services were actually provided during such period)
or to whom at the expiry of the Relevant Period the Company or any Associated Company was actively and directly seeking to supply
goods or services, in either case for the purpose of a Relevant Business; and

 

		(ii)	with whom the Executive or an Employee in a Relevant Business reporting directly to him had dealings
at any time during the Relevant Period or and/or for whom the Executive was responsible and/or about whom he was in possession
of confidential information, in any such case in the performance of his or their duties to the Company or any Associated Company;

 

Nothing in
Clause 18.2(a)(i) will include a person who indicates unequivocally during the first six months of the Relevant Period that such
person would not be a customer for the purposes of that Clause.

 

		(b)	“Competitive Services” means goods or services competitive with those which during
or at the expiry of the Relevant Period the Company or any other member of the Group was supplying or negotiating or actively and
directly seeking to supply to a Customer for the purpose of a Relevant Business, but excluding such types of goods or services
if they were only provided to persons who indicated unequivocally during the first six months of the Relevant Period that they
would not be a customer for the purposes of Clause 18.2 (a)(i);

 

		(c)	“Relevant Business” means the areas of business of the Company or any other member
of the Group in which, pursuant to his duties, the Executive was materially involved, or in respect of which the Executive was
in possession of Confidential Information, in either case at any time during the Relevant Period.

 

    	 	18	 

     

    

 

		(d)	“Territory” means England, Wales, Scotland and/or Northern Ireland and any other country
or, in the United States, any state in which the Company or any other member of the Group is operating or planning to operate Relevant
Business at the expiry of the Relevant Period. Relevant Business will be operating within the Territory at the expiry of the Relevant
Period if it has been conducted or promoted during the Relevant Period;

 

		(e)	“Employee” means a person who:

 

		(i)	is employed in or who renders services to Relevant Business of the Company or any other member
of the Group in a managerial or marketing or sales or distribution or senior capacity;

 

		(ii)	has responsibility for customers of the Company or any other member of the Group or influence over
them; or

 

		(iii)	is in possession of confidential information about the Group’s business;

 

and who in any such
case was so employed and so rendered services during the Relevant Period and who:

 

		(i)	had dealings with the Executive during the Relevant Period; or

 

		(ii)	about whom at the end of the Relevant Period the Executive had confidential or sensitive information
by virtue of the Executive’s duties;

 

		(f)	“Relevant Period” means:

 

		(i)	the period of the Appointment, in relation to the Executive’s actions during the Appointment; and

 

		(ii)	the period of twelve months ending on the last day of the Appointment or the period of the Appointment
if shorter than twelve months, in relation to the Executive’s actions following the end of the Appointment.

 

    	 	19	 

     

    

 

		18.3	Each sub-clause and part of such sub-clause of this Clause constitutes an entirely separate and
independent restriction and does not operate to limit any other obligation owed by the Executive, whether that obligation is express
or implied by law. If any restriction is held to be invalid or unenforceable by a court of competent jurisdiction, it is intended
and understood by the parties that such invalidity or unenforceability will not affect the remaining restrictions.

 

		18.4	The Executive acknowledges that each of the restrictions in this Clause go no further than is necessary
for the protection of the Company’s and each other member of the Group’s legitimate business interests.

 

		18.5	Before accepting any offer of employment, either during the Appointment or during the continuance
of the restrictions in this Clause 18, the Executive will immediately provide to the person making such offer a complete signed
copy of this Agreement.

 

		18.6	Where the Executive’s employment transfers to an employer other than the Company pursuant
to TUPE, the new employer may amend the restrictions, taking into account the new employer’s business, to ensure that the
restrictions in Clause 18 continue to go no further than is necessary for the protection of the legitimate interests of the new
employer (and any group of which it is a member). Subject to any such amendment, or if no such amendment is made, the parties agree
that, following such TUPE transfer, the interpretation of the restrictions in Clause 18 will depend on whether the Relevant Period
includes a period prior to the TUPE transfer. If it does not include such a period, then the references to the Company and Group
shall be understood to refer to the new employer and any Group of which it is a member. Otherwise, the references to the Company
and the Group shall be understood to refer to the new employer and any group in which it is a member only in respect of the portion
of the Relevant Period following the date of the transfer, and the references to the Company and the Group shall apply in respect
of the remainder of the Relevant Period to the employer and the Group as they were immediately prior to the date of transfer.

 

		19.	CONTINUING OBLIGATIONS

 

The termination of the Appointment
will not affect the rights or remedies of either party against the other in respect of any antecedent breach of any of its provisions
or the continuing obligations of the Executive or the Company (as the case may be) under any provision of this Agreement expressed
to have effect after the Appointment has terminated.

 

    	 	20	 

     

    

 

		20.	CORPORATE RECONSTRUCTION

 

If the Appointment
terminates

 

		(a)	by reason of the liquidation of the Company for the purposes of amalgamation or reconstruction;
or

 

		(b)	as part of any arrangement for the amalgamation of the undertaking of the Company not involving
liquidation; or

 

		(c)	as part of any arrangement for the transfer of the whole or part of the undertaking of the Company
to any other member of the Group,

 

and the Executive is offered employment
of a similar nature with any person resulting from such amalgamation or reconstruction or with any person with which the undertaking
of the Company is amalgamated with any other member of the Group on terms which when taken as a whole are not less favourable to
the Executive than the terms of the Appointment, the Executive will have no claim against the Company or any other member of the
Group in respect of the termination of the Appointment by reason of the events described in (a), (b) or (c) of this Clause.

 

		21.	AGREEMENTS WITH OTHER COMPANIES IN THE GROUP

 

		21.1	This Agreement is entered into by the Company for itself and in trust for each other member of
the Group with the intention that each company will be entitled to enforce the terms of this Agreement directly against the Executive.

 

		21.2	The Contracts (Rights of Third Parties) Act 1999 will not create any rights in favour of the Executive
in relation to the benefits granted now or at any time in connection with his employment.

 

		22.	ADDITIONAL TERMS

 

The terms set out in the Schedule
are added in compliance with the requirements of the Employment Rights Act 1996.

 

		23.	NOTICES

 

All notices and other communications
relating to the Appointment will take effect if delivered, upon delivery; if posted, at the earlier of the time of delivery and
(if posted in the United Kingdom by first class post) 10.00am on the second business day after posting; or if sent by facsimile,
when a complete and legible copy of the communication has been received. Any communications posted to the Executive should be sent
to his last known domestic address or his last known home fax number. Any communications posted to the Company should be sent to
the Company’s head office, for the attention of the Company Secretary.

 

    	 	21	 

     

    

 

		24.	MISCELLANEOUS

 

		24.1	This Agreement operates in substitution for and wholly replaces with effect from the Effective
Date all terms previously agreed between the Company and the Executive which will be deemed to have been terminated by mutual consent
and the Executive acknowledges that he has no outstanding claims against any member of the Group in respect of salary or any matter
prior to that date.

 

		24.2	The Appointment constitutes the entire agreement and understanding between the parties and no variation
or addition to it and no waiver of any provision will be valid unless in writing and signed by or on behalf of both parties. The
Company will have no liability or remedy in tort against it in respect of any representation, warranty or other statement (other
than those contained in this Agreement) being false, inaccurate or incomplete unless it was made fraudulently. The Executive acknowledges
that he is not entering into this Agreement in reliance on any representation, warranty or undertaking which is not contained in
this Agreement.

 

		24.3	In the event of any conflict between this Agreement and any Company handbook or policies, the terms
of this Agreement will prevail.

 

		24.4	This Agreement will be construed in accordance with English law and the parties irrevocably submit
to the exclusive jurisdiction of the English Courts to settle any disputes which may arise in connection with this Agreement.

 

EXECUTION

 

The parties have shown their acceptance of
the terms of this Agreement by executing it below at the end of the Schedule.

 

    	 	22	 

     

    

 

SCHEDULE

 

		1.	The following terms of the Appointment apply on the date of the Agreement to which this is a Schedule.

 

		(a)	The Executive’s period of continuous employment will begin on the Effective Date.

 

		(b)	The Executive has no normal working hours but is required to work during normal business hours
and such other hours as may be reasonably necessary for the proper performance of his duties for the Group. The Executive agrees
that the duration of his working time is not measured or pre-determined and can be determined by him in a manner consistent with
the Appointment.

 

		(c)	For Statutory Sick Pay purposes, the Executive’s qualifying days are Monday to Friday.

 

		2.	The following information is supplied pursuant to the Employment Rights Act 1996 and reflects the
Company’s current practice.

 

		(a)	The Executive is expected to exhibit a high standard of propriety, integrity and efficiency in
all his dealings with and in the name of the Company and the Group and may be suspended (with pay) or required to take any accrued
holiday entitlement during any investigation which it may be necessary for the Company to undertake.

 

		(b)	The Company will comply with the terms of its non-contractual disciplinary procedure contained
in the Staff Handbook.

 

		(c)	If the Executive has any grievance relating to the Appointment or matters where he considers the
Company or any other member of the Group is failing to comply fully with its legal obligations, he should refer that grievance
to the Chairman. Should the Executive remain dissatisfied with the decision made, an appeal may be made to the person nominated
by the Company to hear the appeal, who will be a director of the Board not previously involved, or any other person outside the
Group who, in the reasonable opinion of the Company, is appropriate to hear such appeal. The decision of the appeal hearing will
be final and binding.

 

    	 	23	 

     

    

 

EXECUTION

 

	SIGNED by Adam George	)
	duly authorised for and on behalf of	) /s/ Adam George
	GW PHARMACEUTICALS PLC	)
	 	 
	SIGNED by	)
	Julian Gangolli	) /s/ Julian Gangolli

 

    	 	24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]